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Abstract
Background: Malaria vaccine efficacy may be compromised if the frequency of non-target alleles
increases following vaccination with a genetically polymorphic target. Methods are needed to
monitor genetic diversity in polymorphic vaccine antigens, but determining which genetic variants
of such antigens are present in infected individuals is complicated by the frequent occurrence of
mixed infections.
Methods: Pyrosequencing was used to determine allele frequencies at each of six single nucleotide
polymorphisms in the Plasmodium falciparum blood-stage vaccine antigen merozoite surface protein
1 19 kDa (MSP-119) in field samples from a vaccine-testing site in Mali. Mixtures of MSP-119 clones
were created to validate a haplotype-estimating algorithm that uses maximum likelihood methods
to determine the most probable combination of haplotypes given the allele frequencies for an
infection and the haplotypes known to be circulating in the population.
Results: Fourteen unique MSP-119 haplotypes were identified among 351 genotyped infections.
After adjustment to a standard curve, Pyrosequencing provided accurate and precise estimates of
allele frequencies in mixed infections. The haplotype-estimating algorithm provided accurate
estimates of haplotypes in mixed infections containing up to three haplotypes. Based on the MSP-
119 locus, approximately 90% of the 351 infections contained two or fewer haplotypes.
Conclusion:  Pyrosequencing in conjunction with a haplotype-estimating  algorithm provides
accurate estimates of haplotypes present in infections with up to 3 haplotypes, and can be used to
monitor genetic diversity in parasite populations prior to and following introduction of MSP-1-
based malaria vaccines.
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Background
Malaria remains a major cause of disease and death in
tropical regions. A malaria vaccine could contribute to
malaria control, but as with other pathogens (e.g. HIV,
Streptococcus pneumoniae, and influenza virus), malaria
vaccine development is complicated by genetic diversity
in vaccine antigens. Most malaria vaccine antigens have a
high rate of non-synonymous amino acid substitutions
and continue to evolve under selection from the immune
system [1-3]. If immunity conferred by a subunit vaccine
is allele-specific, then vaccination could lead to an
increased frequency of alleles not targeted by the vaccine.
Such changes in the parasite population could compro-
mise vaccine efficacy. It is therefore important to under-
stand the genetic diversity in polymorphic antigens in
endemic populations before and after the introduction of
a malaria vaccine, including the prevalence of different
genetic variants and their natural dynamics, and to meas-
ure allele-specific protective efficacy in clinical trials of
malaria vaccines.
Merozoite Surface Protein 1 is a leading malaria vaccine
candidate antigen. It is the most abundant protein on the
surface of the merozoite and is synthesized as a 195 kDa
precursor. After undergoing proteolytic cleavage, only the
c-terminal 19 kDa remains on the surface of the merozoite
as it enters the erythrocyte [4]. The 19 kDa fragment con-
tains two epidermal growth factor (EGF)-like domains,
which are thought to have an important function in eryth-
rocyte invasion [5]. Antibodies to this region can block
erythrocyte invasion in vitro [4] and are associated with
protection from clinical malaria in field studies [6-8]. The
sequence of MSP-119 is highly conserved [9], which, along
with its putative critical function, make it an attractive vac-
cine target. However, this region has six non-synonymous
single nucleotide polymorphisms (SNPs) at amino acid
positions 1644, 1691, 1699, 1700, 1701, and 1716 [9-
12], which result in expression of different amino acids at
those sites (e.g. EKSNGL, QKSNGF, ETSSRL, etc.). It is not
known whether or how this polymorphism affects immu-
nity.
Determining which genetic variants of polymorphic
malaria antigens are present in infected individuals is
complicated by the frequent occurrence of mixed infec-
tions. When region of interest is amplified using polymer-
ase chain reaction (PCR), the product and subsequent
sequence generated by direct DNA sequencing represents
the pool of all parasite types present in that infection.
Consequently, it is difficult to distinguish which nucle-
otides reside together on one parasite (i.e. haplotypes).
Haplotypes can be identified using PCR cloning [11,13],
since each clone contains a single copy of the amplified
region of interest; however, cloning is time consuming,
expensive, and not all sequences clone with equal effi-
ciency.
Pyrosequencing™ (Biotage, Charlottesville, VA) is a real-
time sequencing method that detects release of pyrophos-
phate during nucleotide incorporation by an enzyme cas-
cade that generates light proportional to the amount of
nucleotide incorporated. This technique allows sequenc-
ing of short stretches of nucleotides (10–20 bp) surround-
ing known polymorphisms without sequencing the rest of
the conserved sequence. Pyrosequencing software can
quantify the proportion of each alternative nucleotide at
each SNP site based on relative peak heights. This method
has been shown to provide accurate and precise measure-
ments of allele frequencies in pools of human DNA
[14,15] and of the degree of DNA methylation [16].
If allele frequencies at each polymorphic site in a candi-
date antigen can be determined, and it is known which
unique haplotypes are circulating in the population, then
a mathematical model can be developed to estimate
which haplotypes are present in mixed infections. In this
study, Pyrosequencing was used to determine allele fre-
quencies at each of the six SNPs in MSP-119, and an algo-
rithm was developed to reconstruct the frequency of MSP-
119 haplotypes in mixed malaria infections. This method
will provide a time- and cost-effective alternative to PCR
cloning for monitoring parasite populations before and
after vaccine introduction.
Methods
Samples and DNA extraction
All samples used in this study were collected at a malaria
vaccine-testing site in Bandiagara, Mali. DNA was
extracted from 3 MM Whatman (Whatman Inc., Clifton,
NJ) filter paper blood samples using a QIAamp DNA Mini
Kit (Qiagen, Valencia, CA). PCR followed by direct
sequencing was used to screen 55 samples collected from
children participating in a case-control study of severe
malaria [17]. PCR followed by Pyrosequencing was used
to screen 296 samples collected from children and young
adults participating in a malaria incidence study [18].
Both the case-control study and the malaria incidence
study were conducted during the years 1999–2001, and
were approved by Institutional Review Boards of the Uni-
versity of Bamako Faculty of Medicine and the University
of Maryland Baltimore. Samples with sequences consist-
ent with the presence of unique  MSP-119 haplotypes were
identified and one representative of each haplotype
underwent PCR cloning.
PCR
PCR primers were designed, using Pyrosequencing Assay
Design Software version 1.0.6 (Biotage, Charlottesville,
VA), to amplify 272 bp of MSP-119 containing the six SNPsMalaria Journal 2006, 5:31 http://www.malariajournal.com/content/5/1/31
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of interest (forward: 5'-CAATGCGTAAAAAAACAAT-
GTCC-3', reverse: 5'-TTAGAGGAACTGCAGAAAATACCA-
3'). The reverse primer contains a 5' biotin label. Each 50
µl PCR contained 33.35 µl sterile distilled water, 5 µl 10×
PCR buffer (Qiagen, Valencia, CA), 4 µl MgCl2 (25 mM),
0.4 µl DNTPs (100 mM with nucleotides mixed in equal
proportions), 1 µl each of forward and reverse primer (5
µM), 0.25 µl HotStarTaq polymerase (Qiagen, Valencia,
CA), and 5 µl template DNA. Cycling conditions were as
follows: 95°C for 15 minutes; 94° for 30 seconds, 65° for
30 seconds, and 72° for 30 seconds for 10 touchdown
cycles -0.5°/cycle; 94° for 30 seconds, 60° for 30 seconds,
and 72° for 30 seconds for 35 cycles; and a final extension
at 72° for 10 minutes. PCR products were visualized on
1.5% agarose gels.
Pyrosequencing
For each Pyrosequencing reaction, 5–10 µl of each bioti-
nylated PCR product (depending on product yield) was
aliquotted into the wells of a 96-well plate. To bind the
products to sepharose beads, 70 µl of binding reaction
mix was added to each well. The binding reaction mix
consists of 40 µl Binding Buffer (Biotage, Charlottesville,
VA), 28 µl high purity water, and 2 µl Streptavidin-Sepha-
rose™ beads (Amersham Biosciences, Piscataway NJ). The
binding reaction mix and PCR products were mixed at
1400 rpm at room temperature for at least five minutes.
Four Pyrosequencing reactions are required to genotype
the six SNPs in MSP-119. Table 1 shows the sequence of
the primers for each Pyrosequencing reaction. Primers
were designed using Pyrosequencing Assay Design Soft-
ware version 1.0.6 (Biotage, Charlottesville, VA). Each
Pyrosequencing primer was diluted to 0.417 µM in
Annealing Buffer (Biotage, Charlottesville, VA), and 12 µl
of the annealing mix (including Pyrosequencing primer)
was added to each well of a PSQ™ HS 96-well plate, result-
ing in 5 pmol of Pyrosequencing primer per well. Negative
controls (i.e. Pyrosequencing primer only and bioti-
nylated primer and Pyrosequencing primer without tem-
plate) were included on each plate to confirm that
background signal was negligible.
Sepharose-bound PCR products were captured on the
probes of the Pyrosequencing Vacuum Prep Tool (Biotage,
Charlottesville, VA). The beads were washed in 70% etha-
nol, followed by denaturation solution (0.2 M NaOH),
and then washing buffer (Biotage, Charlottesville, VA) for
15 seconds each. The vacuum was released, and the
probes were immersed in the PSQ HS 96-well plate con-
taining the annealing solution, and the beads were
released by gentle shaking. The plate was then incubated
on a heat block at 80°C for 2 minutes and allowed to cool
to room temperature prior to reading. Plates were read on
a PSQ HS Pyrosequencer using PSQ HS 96A SNP reagents
and analysis software version 1.2 in AQ mode. Only sam-
ples with single peak signals of at least 30 RLU (relative
luminescence units) were considered suitable for allele
quantification. Samples that gave "wide peak" warnings
upon analysis were also rejected and the Pyrosequencing
repeated.
PCR cloning
For samples chosen for cloning, PCR products were gener-
ated using nonbiotinylated versions of the MSP-119 PCR
primers. These products were cloned using a PCR Cloning
Plus Kit (Qiagen, Valencia, CA). Transformed cells were
plated on LB plates containing 100 mg ampicillin, 80 mg
X-gal, and IPTG. Clones with successful ligations were
chosen by blue-white screening, followed by PCR screen-
ing with MSP-119 PCR primers. Twelve clones were picked
for each ligation. The nucleotide sequence of each clone
was determined using Pyrosequencing and confirmed by
direct sequencing.
Standard curve generation
To account for variation in the accuracy of allele frequency
determination and to standardize across the different
SNPs, standard curves were generated for each of the six
polymorphic positions in MSP-119 (Figure 1). Experimen-
tal mixtures of MSP-119 clones were created to generate
Table 1: Pyrosequencing primers used to genotype polymorphisms in MSP-119.
SNP Primer
Location Nucleotides Amino Acids
1644 G/C E/Q 5'-GCGTAAAAAAACAATGTC-3'
1691 A/C K/T 5'-GTGATGCAGATGCCA-3'
1699a G/A S/N 5'-CCGAAGAAGATTCAGGTA-3'
1700a G/A S/N
1701a G/A G/R
1716b C/T L/F 5'-TCACATGTGAATGTACTAAA-3'
aSNPs at these three positions are genotyped in the same Pyrosequencing reaction.
b Primer sits down prior to position 1711 where there is a rare polymorphism not considered in this analysis.Malaria Journal 2006, 5:31 http://www.malariajournal.com/content/5/1/31
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standard curves and estimate the magnitude of experi-
mental errors. Plasmids were extracted from clones using
a QiaPrep Spin Miniprep kit (Qiagen, Valencia, CA). Plas-
mid concentrations for dilutions and mixtures were deter-
mined using a NanodropTM ND-1000
Spectrophotometer (NanoDrop Technologies, Wilming-
ton, DE). Because no two clones differed at all six SNPs,
two curves were generated: one using clones that differed
at all sites except 1699 and the other using clones that dif-
fered at all sites except 1716. Plasmids were combined in
ratios of 10:0, 9:1, ...1:9, 0:10. TE was added to each mix-
ture to dilute to a final concentration of 1 ng/µl. 2 µl of
Standard curves for each of the six single nucleotide polymorphisms in MSP-119 Figure 1
Standard curves for each of the six single nucleotide polymorphisms in MSP-119. Graphs depict the percent devia-
tion between expected and observed frequencies (y-axis) over a range of expected frequencies (x-axis). Circles indicate the 
observed frequencies, the red line indicates the smoothed data, and the blue line represents the fitted standard curve.Malaria Journal 2006, 5:31 http://www.malariajournal.com/content/5/1/31
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each dilution was used in PCR as described above, and
products underwent Pyrosequencing. To generate stand-
ard curves for each of the SNPs, the deviations between
the expected and observed allele frequencies (i.e. the
errors) were plotted, and a function, Si, was chosen to cor-
rect these errors. Standard curves were chosen from the
family of curves given by the five-parameter function of
the allele frequency, p: a + bp + cp2 - dsin(2gπp). Back-
wards fitting was used to find the most parsimonious
function Si for each of the SNPs (Table 2). Thus, given a set
of measured frequencies pi, the best estimate of the actual
frequencies is Si(pi).
Haplotype estimation
The haplotype-estimating algorithm uses maximum like-
lihood methods to determine the most probable combi-
nation of haplotypes given the allele frequencies for an
infection, the haplotypes known to be circulating in the
population (Table 3), and a probability distribution of the
measurement errors. To estimate the distribution of meas-
urement errors associated with each SNP (i.e. the residual
errors after adjustment to the standard curve), the abso-
lute values of the errors were assumed to be exponentially
distributed. The mean residual error for each SNP, εi, was
calculated using the same clone mixtures that were used to
generate the standard curve data. Given a putative set of
haplotype frequencies, fi, and a set of allele frequencies, pi,
the negative log-likelihood of fi is  ∑i(|A(fi) - S(pi)|/εi),
where A (fi) indicates the allele frequencies for a putative
combination of haplotypes, S(pi) represents observed
allele frequencies adjusted to the standard curve, and εi is
the mean residual error for each SNP. To estimate the mul-
tiplicity of infection (MOI) for each infection, Mi, the
number of haplotypes per infection was assumed to be
distributed as a conditional Poisson [19] (i.e. each infec-
tion has at least one haplotype) with a mean of 1.38 hap-
lotypes (estimated from 296 infections from the
Bandiagara malaria incidence study). Thus, the full equa-
Table 2: Standard Curves. Functions used to adjust Pyrosequencing allele frequencies for six polymorphic sites in MSP-119.
SNP Location Function* Parameter values
ab c d g
1644 a - dsin(2πp) -0.00497 - - 0.0292 -
1691 a+bp+cp2 - dsin(2πp) 0.00894 0.176 -0.170 0.0162 -
1699 bp - dsin(2πp) - 0.0522 - 0.0261 -
1700 bp + cp2 - dsin(2πp) - 0.0966 -0.0851 0.0219 -
1701 a+cp2 - dsin(2πp) -0.0303 - 0.133 0.0223 -
1716 -dsin(2gπp) - - - 0.0311 1.051
*Where p is the allele frequency at the SNP of interest
Table 3: MSP-119 haplotypes observed in Bandiagara, Mali and confirmed by PCR Cloning
Haplotype Amino Acid Position
1644 1691 1699 1700 1701 1716
(E/Q) (T/K) (S/N) (S/N) (R/G) (L/F)
1QKSNGL
2EKSN GL
3ETSSRL
4QKNNGL
5EKSSRL
6QKSNGF
7QTSSRL
8ETSN GL
9ETSSGL
10 E K N N G L
11 E K S N G F
12* Q K S S R L
13* Q K S S G L
14* Q T S S G L
* Not previously reported in the literature.Malaria Journal 2006, 5:31 http://www.malariajournal.com/content/5/1/31
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tion for the negative log likelihood is ∑i[(|A(fi) - S(pi)|/εi)
- log(POIS(Mi-1, 0.38))].
Finding the combination of haplotype frequencies, fi, that
maximizes the likelihood is hampered by the possibility
of finding multiple local maxima. To address this concern,
a simple optimization procedure was used with a large set
of starting conditions. Starting conditions were chosen by
assuming the maximum number of haplotypes per infec-
tion was seven and finding all combinations of haplo-
types that could explain the allele frequencies in the
sample by solving a reduced linear system of equations
(Figure 2). The software was written in R (R Foundation
for Statistical Computing, Vienna, Austria) and is availa-
ble upon request.
Validation of haplotype-estimating algorithm
Experimental mixtures of plasmids from MSP-119 clones
were made to determine the algorithm's ability to cor-
rectly estimate the haplotypes present in mixed malaria
infections. Plasmids were mixed in the proportions listed
in Table 4. Like the mixtures used to generate the standard
curves, each mixture had a final concentration of 1 ng/µl
and 2 µl were used as the template for PCR. Allele frequen-
cies at each SNP were determined using Pyrosequencing
as described above. Input for the algorithm included the
standard curve adjusted allele frequencies for each sample
and the list of 14 haplotypes observed in the study popu-
lation.
Human subjects approval
Samples were collected under protocols reviewed and
approved by Institutional Review Boards of the University
of Maryland School of Medicine and the University of
Mali Faculty of Medicine. Informed consent was obtained
from all study participants or their guardians.
Results
MSP-119 haplotypes in Bandiagara, Mali
A total of 20 samples underwent PCR cloning. Sequencing
of the clones from these samples identified 14 unique
MSP-119 haplotypes circulating in the study population.
The observed haplotypes are listed in Table 3. Three of
these haplotypes have not been previously reported (i.e.
QKSSGL, QKSSRL, and QTSSGL).
Accuracy and precision of allele frequency determination
Several factors can affect relative peak heights generated
during Pyrosequencing, including the bases flanking the
polymorphic site (homopolymer formation occurs when
adjacent nucleotides are identical to one of the alleles at
the SNP site), increased signal from "A" alleles due to the
use of dATPαS instead of dATP in the Pyrosequencing
reaction, and background signal [14]. To account for these
sources of variation and to standardize across the different
SNPs, standard curves were generated for each of the six
polymorphic positions in MSP-119. Four replicates of each
dilution were genotyped on two different days. There was
no statistically significant difference between replicates
run on different days (data not shown). The deviation
between the expected and observed allele frequencies for
all replicates was plotted over the range of expected fre-
quencies (Figure 1). For each SNP, a standard curve was
fitted to the data. As observed in Figure 1, the allele fre-
quencies at site 1701 required the most adjustment, with
a correction of ~10% required as the frequency of the G
allele approached 100%. The other five SNPs required
allele frequency corrections of <10%. Raw allele frequen-
cies for each SNP were adjusted to the standard curve prior
to haplotype estimation.
The mean residual errors for each SNP (i.e. the mean dif-
ference between adjusted individual observations and the
standard curve) were 1.8%, 3.7%, 3.2%, 2.0%, 4.3%, and
1.8%, respectively for positions 1644, 1691, 1699, 1700,
1701, and 1716. These data suggest that allele frequency
measurements at positions 1701 and 1691 were the least
precise; however, all mean errors were less than 5%.
Validation of haplotype-estimating algorithm
To test the algorithm's ability to correctly estimate the
haplotypes present in mixed malaria infections, plasmids
from MSP-119 clones were used to make mixtures with
known frequencies of various MSP-119 haplotypes. These
mixtures then underwent PCR, Pyrosequencing, and hap-
Linear system of equations to choose starting conditions for  haplotype estimation Figure 2
Linear system of equations to choose starting condi-
tions for haplotype estimation. To address the concern 
of finding multiple local maxima during haplotype estimation, 
starting conditions were chosen by assuming the maximum 
number of haplotypes per infection was seven and finding all 
combinations of haplotypes that could explain the allele fre-
quencies in the sample by solving a reduced linear system of 
equations.
f1
f2
f3
f4
f5
f6
f7
f8
f9
f10
f11
f12
f13
f14
Q
K
S
N
G
L
fii
p1
p2
p3
p4
p5
p6
1
1  0  0  0  0  1  0 1  1  0  1  1  1  0 
1  1  0  0  0  1  1 1  0  1  1  1  0  1 
1  1  1  1  1  1  1 0  1  0  1  1  1  1
1  1  0  0  1  1  0 1  0  1  0  0  0  1
1  1  0  1  1  1  0 1  0  1  0  1  1  1
1  1  1  1  1  0  1 1  1  1  1  1  1  0
1  1  1  1  1  1  1 1  1  1  1  1  1  1
=
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lotype-estimation. The actual and estimated haplotypes
and their frequencies are shown in Table 4. Based solely
on maximum likelihood, the algorithm does very well
estimating up to three haplotypes. Haplotype estimation
is less accurate for four or more haplotypes. Examining
the algorithm output for the higher multiplicity of infec-
tion (MOI) mixtures shows that the model yields multiple
"good" answers with similar likelihoods, and conse-
quently it is difficult to choose which "good" answer is
correct (i.e. identifiability becomes a problem with high
MOI infections). However, lower MOI infections make up
a majority of the infections observed in Mali (Figure 3).
Based on data from 296 infections from a malaria inci-
dence study in Bandiagara, Mali, nearly 90% of infections
have one or two MSP-l19 haplotypes (Figure 3).
Discussion
A high-throughput method that combines allele fre-
quency determination by Pyrosequencing with a mathe-
matical model was developed to estimate the MSP-119
haplotypes present in mixed malaria infections. After
adjustment to a standard curve, Pyrosequencing yields
accurate and precise estimates of the relative frequency of
alleles in mixed infections. The haplotype-estimating
algorithm uses maximum likelihood methods to deter-
mine the most probable combination of haplotypes given
the allele frequencies for an infection and the haplotypes
known to be circulating in the population, and provides
accurate estimates of haplotypes present in lower multi-
plicity of infection (MOI) infections (≤3 types). For higher
MOI infections (≥4 types), the algorithm gives statistically
reasonable, but less accurate, estimates. The reduced accu-
Table 4: Validation of haplotype-estimating algorithm. Known haplotype frequencies present in artificial mixtures of MSP-119 clones 
were compared to maximum likelihood estimates of haplotype frequencies generated using the algorithm.
Mixture Actual Haplotype (%) Maximum Likelihood Estimate Haplotype (%)
1234512345
1Q K S N G L  
(70)
EKSNGL 
(30)
QKSNGL 
(73)
EKSNGL 
(27)
2Q K S N G L  
(30)
EKSNGL 
(70)
QKSNGL 
(37)
EKSNGL 
(63)
3Q K S N G L  
(70)
ETSNGL 
(30)
QKSNGL 
(72)
ETSNGL 
(28)
4Q K S N G L  
(30)
ETSNGL 
(70)
QKSNGL 
(33)
ETSNGL 
(67)
5E K S S R L  
(70)
ETSNGL 
(30)
EKSSRL 
(70)
ETSNGL 
(30)
6E K S S R L  
(30)
ETSNGL 
(70)
EKSSRL 
(29)
ETSNGL 
(63)
EKSNGF 
(07)
7Q K S N G F  
(70)
EKSSRL 
(30)
QKSNGF 
(75)
EKSSRL 
(25)
8Q K S N G F  
(30)
EKSSRL 
(70)
QKSNGF 
(38)
EKSSRL 
(62)
9 ETSSRL 
(35)
QKNNGL 
(15)
QKSNGL 
(50)
ETSSRL 
(31)
QKNNGL 
(14)
QKSNGL 
(55)
10 ETSSRL 
(15)
QKNNGL 
(35)
QKSNGL 
(50)
ETSSRL 
(14)
QKNNGL 
(38)
QKSNGL 
(49)
11 QKSNGL 
(47)
EKSNGL 
(20)
EKSSRL 
(33)
QKSNGL 
(50)
EKSNGL 
(21)
EKSSRL 
(29)
12 QKSNGL 
(20)
EKSNGL 
(47)
EKSSRL 
(33)
QKSNGL 
(21)
EKSNGL 
(49)
EKSSRL 
(31)
13 ETSSRL 
(23)
QKNNGL 
(10)
QKSNGL 
(33)
EKSNGL 
(33)
ETSSRL 
(21)
QKNNGL 
(15)
QKSNGL 
(31)
EKSNGL 
(33)
14 ETSSRL 
(10)
QKNNGL 
(23)
QKSNGL 
(33)
EKSNGL 
(33)
ETSSRL 
(10)
EKNNGL 
(30)
QKSNGL 
(60)
15 QKSNGL 
(31)
EKSNGL 
(13)
EKSSRL 
(22)
ETSSRL 
(33)
EKSNGL 
(49)
EKSSRL 
(18)
QTSSRL 
(33)
16 QKSNGL 
(13)
EKSNGL 
(31)
EKSSRL 
(22)
ETSSRL 
(33)
QKSNGL 
(14)
ETSNGL 
(33)
EKSSRL 
(53)
17 ETSSRL 
(15)
QKNNGL 
(07)
QKSNGL 
(22)
EKSNGL 
(22)
QKSNGF 
(33)
QTSSRL 
(14)
QKNNGL 
(07)
QKSNGL 
(47)
EKSNGF 
(32)
18 QKSNGL 
(21)
EKSNGL 
(09)
EKSSRL 
(15)
ETSSRL 
(22)
QKSNGF 
(33)
ETSNGL 
(17)
EKSNGL 
(22)
QKSSRL 
(31)
QKSNGF 
(30)
* Haplotypes indicated in bold type are not present and represent errors in haplotype estimation.Malaria Journal 2006, 5:31 http://www.malariajournal.com/content/5/1/31
Page 8 of 10
(page number not for citation purposes)
racy at high MOI is primarily due to the inability of the
algorithm to choose between several haplotype combina-
tions with similar likelihoods.
Because MSP-119 is highly conserved, measures of MOI
based on this locus are likely to be lower than those based
on more polymorphic loci (e.g. MSP-1 block 2 or MSP-2).
Therefore it may be acceptable to have an algorithm with
greater accuracy at lower MOI. In Mali, the vast majority
of samples have low MOI (≤3 types) based on this locus.
In 24 infections from six infants living in a high transmis-
sion area of western Kenya, the largest number of MSP-119
haplotypes observed in an infection was two; however,
the largest number of clones picked per sample was four,
and it is possible that higher MOIs would have been
observed had more clones been picked [11]. At a popula-
tion level, with large sample sizes, the inaccurate estima-
tion of some haplotypes in a small number of high MOI
infections is not likely to be statistically relevant. When
individual histories are of interest, it may be possible to
fine-tune the algorithm to allow more accurate estimation
of high MOI infections by using information about the
haplotypes present in low MOI infections that come
before and after the high MOI infection to choose the
"best" answer out of several statistically "good" answers.
Identifiability problems will also increase as the number
of circulating haplotypes in a population increases. There-
fore, in areas of high transmission where there may be
more circulating haplotypes, it may be necessary to restrict
the algorithm to include the most common haplotypes.
By doing so, the algorithm should be able to resolve most
of the infections, and will be unable to resolve infections
that contain rare haplotypes. These rare haplotypes can
then be identified using other methods such as PCR clon-
ing.
Similar expectation-maximization methods have been
used to estimate haplotype frequencies in diploid human
populations [20,21] and in pooled human DNA [22,23].
The expectation-maximization (EM) algorithm developed
by Excoffier and Slatkin uses maximum likelihood meth-
ods to determine the most probable haplotype assign-
ment given the observed sample genotypes and the
estimated population haplotype frequencies (under the
assumption of Hardy-Weinberg equilibrium). This
method works best for large sample sizes, and uses several
sets of starting conditions to avoid convergence on local
maxima [20]. Stephens and colleagues use a Bayesian
method to reconstruct haplotypes based on both the like-
lihood and an a priori assumption that unresolved haplo-
types tend to be similar to known haplotypes [21]. The
EM algorithm has recently been applied toward resolving
haplotypes in pooled human DNA samples [22,23]. Sim-
ilar to the algorithm described in this study, haplotype
estimation in pooled human DNA samples is most accu-
rate when the pool consists of fewer individuals. Ito et al.
achieved the most accurate estimates with pools contain-
ing fewer than four individuals [22], while Quade et al.
achieved accurate estimates for up to ten pooled samples
(using only two alleles at two loci) [23]. These studies
indicate that lack of identifiablity in samples with larger
numbers of haplotypes is a common limitation of these
types of algorithms.
The accuracy of Pyrosequencing allele quantification can
be affected by several factors including having an "A"
allele in the SNP and having flanking bases identical to
one or the other alternative alleles in the SNP (i.e.
homopolymer formation). Given the A/T rich genome of
Plasmodium, four out of six SNPs in MSP-119 contain an
"A" allele. In addition, five of the six SNPs in 19 kDa form
homopolymers with flanking alleles. Therefore, it is
important to adjust the allele frequencies to a standard
curve to improve accuracy. However, since allele frequen-
cies of replicate runs of the same sample on different days
did not differ significantly, one standard curve can be used
to adjust all the data (as opposed to generating a curve
every day the assay is run).
Several methods have been used to determine allele fre-
quencies in mixed malaria infections including PCR clon-
ing [11,24], real-time quantitative PCR (RTQ-PCR) [25],
and proportional sequencing [26]. All of these methods,
including Pyrosequencing, have advantages and disad-
vantages. PCR cloning gives definitive haplotypes; how-
ever, it is the most time-consuming and expensive of the
methods, which significantly limits the number of sam-
ples that can be feasibly analyzed using this method. In
addition, because Plasmodium often uses codons different
than those used by the competent bacteria used in clon-
ing, not all sequences can be cloned efficiently. RTQ-PCR
Multiplicity of infection based on MSP-119 Figure 3
Multiplicity of infection based on MSP-119. The number 
of MSP-119 haplotypes observed per infection (multiplicity of 
infection), among 296 infections from Bandiagara, Mali, as 
determined by Pyrosequencing followed by haplotype esti-
mation.
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is a more sensitive method than Pyrosequencing at detect-
ing very low frequency alleles (<5%); however, it has a
lower throughput and requires more optimization than
Pyrosequencing. Like RTQ-PCR, Pyrosequencing assays
are designed to detect known polymorphisms. Methods
that rely on sequencing an entire region or gene of interest
(e.g. PCR cloning) are better for detecting new SNPs. Pro-
portional sequencing is a method that estimates allele fre-
quencies in mixed infections by measuring the peak
heights in direct sequencing electropherograms [26].
While this method has similar applications and accuracy
as Pyrosequencing, it is more expensive and has a lower
throughput [26]. Because Pyrosequencing sequences
short stretches of nucleotides (10–20 bp), for certain very
polymorphic loci (e.g. domain I of P. falciparum apical
membrane antigen-1, another vaccine candidate antigen),
it is not possible to set down a sequencing primer every 20
bp. In this instance, proportional sequencing may be
more appropriate. If MSP-119 haplotypes are of interest,
allele frequencies from any of these methods can be used
with the haplotype-estimating algorithm described here.
The cost of equipment for Pyrosequencing is similar to
that for standard DNA sequencing, which is now done in
several sub-Saharan African countries, including Mali.
Pyrosequencing may be suitable for other applications
such as typing known single nucleotide polymorphisms
in parasite genes that serve as molecular markers for drug
resistant malaria.
Conclusion
In conclusion, Pyrosequencing is a technique that allows
reliable quantification of alleles in mixed malaria infec-
tions. It is fast, relatively inexpensive, and can be used to
genotype polymorphisms of interest in many important
Plasmodium  genes such as those responsible for drug
resistance, immunity, and virulence. In this study, Pyrose-
quencing was adapted to measure the frequency of alleles
in an erythrocytic vaccine candidate antigen MSP-119 and
combined with a haplotype-estimating algorithm to esti-
mate the frequency of MSP-119haplotypes in infected
individuals. This method is being used to understand the
natural dynamics of MSP-119, at both population and
individual levels, at a malaria vaccine-testing site in Ban-
diagara, Mali, and can be used to monitor populations
during large-scale vaccine trials to determine allele-spe-
cific vaccine efficacy.
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